Alluvi, previously BI 4744, represents a notable breakthrough in weight loss treatment. This dual stimulator targeting both glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide targets demonstrates https://alluvi-research.co.uk/product/tirzepatide-40mg-rd-only-alluvi/